Development and validation of a prognostic nomogram for HIV/AIDS patients who underwent antiretroviral therapy: Data from a China population-based cohort

Xiangqing Hou\textsuperscript{a,b,1}, Dayong Wang\textsuperscript{c,1}, Jingjing Zuo\textsuperscript{d}, Jushuang Li\textsuperscript{a,b}, Tao Wang\textsuperscript{a,b}, Chengnan Guo\textsuperscript{a,b}, Fang Peng\textsuperscript{a,b}, Dehua Su\textsuperscript{c}, Lina Zhao\textsuperscript{c}, Zhenmiao Ye\textsuperscript{c}, Hemei Zhang\textsuperscript{c}, Chao Zheng\textsuperscript{c}, Guangyun Mao\textsuperscript{a,b,d,∗}

\textsuperscript{a} Department of Preventive Medicine, School of Public Health \& Management, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China
\textsuperscript{b} Center on Evidence-Based Medicine \& Clinical Epidemiology, School of Public Health \& Management, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China
\textsuperscript{c} Wenzhou Center for Disease Prevention and Control, Wenzhou, Zhejiang, 325000, China
\textsuperscript{d} School of Ophthalmology \& Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China
\textsuperscript{∗} The Second Affiliated Hospital of Zhejiang University School of Medicine, No.88, Jiefang Road, Hangzhou, Zhejiang, 310000, China

\textbf{Article Info}

\textbf{Article history:}
Received 25 August 2019
Revised 28 September 2019
Accepted 28 September 2019
Available online 5 October 2019

\textbf{Keywords:}
PLHIV
Nomogram
Prognosis
HIV/AIDS-related mortality
DCA

\textbf{Data for reference}
The datasets generated and/or analysis during the current study are not publicly available due to the protection of the privacy of people living with HIV/AIDS but are available from the corresponding author on reasonable request.

\textbf{Abstract}

\textbf{Background:} Accurate forecast of the death risk is crucial to the administration of people living with HIV/AIDS (PLHIV). We aimed to establish and validate an effective prognosis nomogram in PLHIV receiving antiretroviral therapy (ART).

\textbf{Methods:} All the data were obtained from 2006 to 2018 in the Wenzhou area from China AIDS prevention and control information system. Factors included in the nomogram were determined by univariate and multiple Cox proportional hazard analysis based on the training set. The receiver operating characteristic (ROC) and calibration curves were used to assess its predictive accuracy and discriminative ability. Its clinical utility was also evaluated using decision curve analysis (DCA), X-tile analysis and Kaplan-Meier curve, respectively in an independent validation set.

\textbf{Findings:} Independent prognostic factors including haemoglobin, viral load and CD4\textsuperscript{+} T-cell count were determined and contained in the nomogram. Good agreement between the prediction by nomogram and actual observation could be detected in the calibration curve for mortality, especially in the first year. In the training cohort, AUC (95\% CI) and C-index (95\% CI) were 0.93 (0.90, 0.96) and 0.90 (0.85, 0.96), respectively. In the validation set, the nomogram still revealed excellent discriminations [AUC (95\% CI): 0.95 (0.91, 1.00)] and good calibration [C-index (95\% CI): 0.92 (0.82–1.00)]. Moreover, DCA also demonstrated that the nomogram was clinical beneficial. Additionally, participants could be classified into three distinct (low, middle and high) risk groups by the nomogram.

\textbf{Interpretation:} The nomogram presents accurate and favourable prognostic prediction for PLHIV who underwent ART.

\textbf{Funding:} This work was supported by Zhejiang Basic Public Welfare Research Project (LGF19H260011), Wenzhou Basic Public Welfare Research Project (Y20180201), the Initial Scientific Research Fund (KYQD170301), the Major Project of the Eye Hospital Wenzhou the Major Project of the Eye Hospital Wenzhou Medical University (YNZD201602). Part of this work was also funded by National Natural Science Foundation of China (81670777) and Science and Technology Innovation Activity Plan and New Tal-

\textbf{Abbreviations:} BMI, body mass index; PLT, platelet; ALB, albumin; TBIL, total bilirubin; TB, tuberculosis; WBC, white blood cell; VL, viral load; HB, haemoglobin; CR, Creatinine; TG, Triglyceride; GLU, Fasting plasma glucose; TC, total cholesterol; ALT, alanine transaminase; AST, aspartate transaminase; C-index, concordance index; ROC, receiver operating characteristics; AUC, area under curve; CI, confidence interval; DCA, decision curve analysis; NB, net benefit.

\textsuperscript{∗} Corresponding author at: Department of Preventive Medicine, School of Public Health \& Management, School of Ophthalmology \& Optometry, School of Biomedical Engineering, Wenzhou Medical University, Chashan University Town, Wenzhou, 325035, China.
E-mail address: mgy@wmu.edu.cn (G. Mao).

\textsuperscript{1} These authors contributed equally to this work.

https://doi.org/10.1016/j.ebiom.2019.09.031
2352-3964/© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Introduction

Although a proportion of people living with HIV (PLHIV) with access to antiretroviral therapy (ART) have a life expectancy similar to the general population, the increased mortality of many PLHIV still can’t be ignored and there has been increasing focus on the management of PLHIV. Unfortunately, there is no universal and widely recognized applicable scoring system to predict the mortality of PLHIV who underwent ART. Therefore, we aimed to develop and validate a risk scoring system among patients who underwent ART. This approach would allow us to better identify patients with a high risk of mortality, which would facilitate a more personalized approach to managing these cases.

Evidence before this study

Several studies have shown that some laboratory indicators are closely related to the mortality of PLHIV and other HIV-related co-morbidities [4–6]. For example, Bansal et al. [7] suggest that alanine transaminase (ALT), albumin, alkaline phosphatase (AP) and haemoglobin (HB) to be used to predict mortality risk of PLHIV. Moreover, the platelet-associated index is reported to be closely related to the disease progression of PLHIV and still found to be a predictor of PLHIV combined with community-acquired pneumonia (CAP) mortality [6,8]. In practice, a single indicator is often insufficient in predicting the prognosis of the disease and does not achieve satisfying results. However, the combination of several independent indicators may highly improve predictive effectiveness. Since multiple risk factors of HIV/AIDS-related mortality have been identified, some scoring systems have been formulated to predict mortality [9–11], unfortunately, there is no universal and widely recognized applicable scoring system to predict the mortality of PLHIV who underwent ART.

In recent years, more and more researches have focused on laboratory testing indicators to predict survival and prognosis of diseases [12,13]. For example, several risk factors have been formulated based on baseline data of PLHIV on ART to assess short-term disease prognosis [14–16], however, few available predictive models are well validated. As a simpler, more intuitive and advanced approach, nomogram is more and more commonly used in the prognostic analysis. It simplifies the predictive model to the probability of an event. Besides, it also provides a user-friendly interface for clinical usage [17]. Though prognosis nomograms models for predicting the death risk of PLHIV have been developed and validated based on previous studies, the performance is unsatisfactory. For instance, Margaret et al. [18] have developed a nomogram model with the concordance index (95% CI) of 0.75 (0.74, 0.81) in the training set and 0.69 (0.59, 0.77) in the validation cohort. This nomogram model can’t be unsatisfied, but far from excellent. As far as we know, few previous studies have formulated prognostic models of PLHIV receiving ART with satisfied discrimination and excellent calibration. Depending on common laboratory and clinical indicators of 12 years of follow up from the AIDS Prevention and Control Information System (AIDS-PCIS) in the Wenzhou area, we aimed to develop a simple and effective nomogram scoring system (NSS) to foresee the personalized death risk of PLHIV. To improve the robustness and reliability of our conclusion, a propensity-score matching (PSM) approach was applied at a 1:4 ratio to determine the participants, in which a case (dead PLHIV) was matched by age and gender with 4 controls (alive PLHIV). To make our findings more credible, the enrolled study participants were then randomly split into a training and another separate validation sets, depending on the block, at a ratio of 7:3 without replacement. The association between the presence of death and potential prognostic factors from both clinical and laboratory data were comprehensively analysed within the training set. Besides, the effect on the performance, discrimination and calibration of the nomogram model were thoroughly assessed based on the training and validation set, respectively. Meanwhile, the performance of the NSS has also been assessed by a decision curve analysis. Potential overfitting has also been well considered in the current study. The individual survival probability of each participant was obtained by the nomogram based on the training set, and extensively validated in a separate validation set.

Added value of this study

We established an effective and accurate nomogram model including haemoglobin (HB), viral load (VL) and CD4+ T-cell count for the evaluation mortality of PLHIV receiving ART in the present study and the superiority of our nomogram also reflects on the clinical utility. This would be very favourable to promote the precise prevention and personalized health management of PLHIV to maximize cost-effectiveness.

Implications of all the available evidence

The nomogram in the present study was completely an optimal prognostic model for evaluating the mortality of PLHIV, containing VL, CD4 and HB, and with satisfying stability and accuracy, for the prediction of PLHIV mortality was successfully developed and carefully evaluated.

1. Introduction

In the past several decades, HIV/AIDS is still one of the leading health problems worldwide [1]. Thanks to the era of universal scaling-up antiretroviral therapy (ART), more and more people living with HIV (PLHIV) nowadays have received ART as suggested by WHO regardless of their CD4+ T-lymphocyte (CD4) counts [1,2]. Although a proportion of PLHIV with access to ART have a life expectancy similar to the general population, the increased mortality of many PLHIV still can’t be ignored. So, an in-time accurate forecast of the death risk amongst PLHIV is crucial for clinicians and health care providers to perform effective PLHIV administration [3].

Several studies have shown that some laboratory indicators are closely related to the mortality of PLHIV and other HIV-related co-morbidities [4–6]. For example, Bansal et al. [7] suggest that alanine transaminase (ALT), albumin, alkaline phosphatase (AP) and haemoglobin (HB) to be used to predict mortality risk of PLHIV. Moreover, the platelet-associated index is reported to be closely related to the disease progression of PLHIV and still found to be a predictor of PLHIV combined with community-acquired pneumonia (CAP) mortality [6,8]. In practice, a single indicator is often insufficient in predicting the prognosis of the disease and does not achieve satisfying results. However, the combination of several independent indicators may highly improve predictive effectiveness.
began after starting ART in which each PLHIV was visited by per three months strictly following the current clinical guidelines until December 31, 2018, and the antiviral drugs were distributed free of charge [22]. The inclusion criteria were as follows: 1) Having complete laboratory blood tests before receiving ART; 2) Being visited at least once; 3) Living in Wenzhou area including temporary residents; 4) Over 15 years old; 5) Being identified from January 2006 to December 2018. The survival time was defined as the duration from receiving the first ART to death or December 31, 2018.

At the end of the 12 years’ follow-up, 150 PLHIV died due to HIV/AIDS-related diseases and were determined as the cases in this nested case-control study. To improve the comparison and the stability of the results to some extent, the cases and controls were matched by the age and gender at a ratio of 1:4 using a propensity score matching (PSM) approach [23]. As a result, a total of 750 subjects, consisting of 150 dead and 600 alive PLHIV, were identified in the current study, and classified into 150 blocks, which were then randomly split into a training set and another separate validation set at a ratio of 7:3. The flowchart of recruitment participants is shown in the supplement Fig. S1.

2.2. Clinical information and laboratory reports

Data on demographics and clinical characteristics of participants were collected in a face-to-face investigation manner at their enrolment or extracted from their medical records utilizing a structured questionnaire specifically designed for AIDS-PCIS. The information included age, sex, height, weight, marital status, occupation, history of the sexually transmitted disease (STD), disease stage, the origin of identification, the world health organization (WHO) clinical staging, infection pathway and others. Body mass index (BMI) was calculated using the formula: BMI = weight (kg)/[height (m)]².

Information on the laboratory test was obtained from Wenzhou CDC or local hospital. The laboratory testing indicators were consisted of CD4+ T lymphocytopenia (CD4), CD8+ T lymphocytopenia (CD8), viral load (VL), white blood cell (WBC), Platelet (PLT), haemoglobin (HB), serum creatinine (CR), triglyceride (TG), serum total cholesterol (TC), fasting plasma glucose (GLU), alanine aminotransferase (ALT), aspartate transaminase (AST), total bilirubin (TBIL) and others. All of these laboratory assessments were conducted at each visit in the central laboratory of local hospitals or Wenzhou CDC by the same trained technicians strictly following the clinical guidelines.

The routine blood biochemical examination such as TG, TC, GLU, CR, AST, ALT and TBIL were applied using the Beckman AU5800 automatic biochemical analyser (BECKMAN COULTER K., Japan). Other blood tests including WBC, HB and PLT were performed using the Sysmex Xe-2100 automatic blood cell analyzer (SYMSMEX CORPORATION, Japan). Moreover, CD4 and CD8 were determined using the BD FACSCalibur flow cytomter (Becton Dickinson Corporation, USA). VL was assessed using nucleic acid sequence-based amplification, NASBA™, NucliSens EasyQ KPC (bioMérieux, France).

2.3. Ethics statement

The data utilized for the present study were extracted from AIDS-PCIS, which was established by National Centre for AIDS/sexually transmitted disease Control and Prevention of Chinese Centre for Disease Control and Prevention (CCDC) to generate the HIV/AIDS epidemic database with continued enrolment of HIV-infected person. The protocol of AIDS-PCIS establishment had been approved by the institutional review boards at CCDC and informed consents were obtained before the subjects’ enrolment. Furthermore, the protocol of the current study was also approved by the ethical review board of Wenzhou Centre for Disease Control and Prevention.

2.4. Statistical analysis

As missing values will lead to bias on the results to some extent, multiple imputations were applied to achieve suitable values for those missing data before the data analysis. A sensitivity analysis was also carried out in the current study to evaluate the effect of missing value filling (Supplement Table S1). To improve the robustness and reliability of our conclusion, the enrolled 150 blocks of participants containing 150 dead and 600 alive PLHIV were split into a training set and another separate validation set in a random manner without replacement at a ratio of 7:3. The comparability of the two sets was then evaluated (Table 1). Continuous variables with normal distribution were presented as the mean ± standard deviation ( ± ) and student t-tests were used to infer the differences between the training and validation sets. For those with obviously skewed distribution, median (1st quartile, 3rd quartile) and chi-square or Fisher’s exact tests would be applied for their comparisons.

Depending on the training set, univariate and multivariable Cox proportion hazard regression models were used to screen potential prognostic factors and estimate their weights. According to the Akaike information criterion (AIC), we developed a series of different multivariable models. Factors with p-values, which were calculated based on multivariable Cox proportion hazard regression models, over 0.05 were removed from the associated models. Moreover, according to Occam’s Law of Razor, the best model for achieving optimal results are models with fewer variables [24]. As a result, a candidate nomogram model with appropriate predictive ability was screened depending on the three most significant risk factors. The predictive performance of nomogram and other models to predict the survival were quantified using the area under the curve (AUC) of the receiver operating characteristic (ROC) analysis and the consistency index (C-index) [25], and comprehensively evaluated based on the training set and validation set, respectively. It was reported that the c-index, a generalization of the AUC, was developed by Royston and Sauerbrei [26] to represent the probability of the concordance between the observed and predicted survival. The performance of the nomogram was also performed with calibration. Moreover, the clinical utilities of the nomogram were also carefully investigated using decision curve analysis (DCA), X-tile analysis and Kaplan-Meier curves in an independent validation set, respectively to make up the limitations of ROC curves, which could not achieve the best sensitivity and specificity at the same time.

All data management and statistical analyses were carried out using Stata/MP 15.1 for windows (Copyright 1985-2017 Stata Corp LLC, College Station, Texas 77845, USA). Figures were drawn with R-Studio for windows (Version 1.2.1335 Copyright 2009–2019 R-Studio, Inc.). All tests were two-sided and P ≤ 0.05 was set as the significant level.

3. Results

3.1. Characteristics of participants

In this PSM based nested case-control study, the characteristics of the 750 PLHIV (525 from the training set and 225 from the validation set) revealed that both sets were similar in all variables (Table 1). During the period of follow-up, a total of HIV/AIDS-related mortality was 73.1 per 1000 person-years in the training
Table 1
Baseline demographics and clinical characteristics of patients in training cohort and validation cohort.

| Variables                        | Training set (N = 525) | Validation set (N = 225) | P   |
|----------------------------------|------------------------|--------------------------|-----|
| **Discrete variables**           |                        |                          |     |
| **Gender**                       |                        |                          | 0.119|
| Men                              | 436 (83.0)             | 197 (87.6)               |     |
| Woman                            | 89 (17.0)              | 28 (12.4)                |     |
| **Hepatitis B Virus**            |                        |                          | 0.849|
| Positive                         | 68 (13.0)              | 28 (12.4)                |     |
| Negative                         | 457 (87.0)             | 197 (87.6)               |     |
| **Tuberculosis**                 |                        |                          | 0.932|
| Yes                              | 24 (4.6)               | 9 (4.0)                  |     |
| No                               | 488 (93.0)             | 210 (93.3)               |     |
| **WHO**                          |                        |                          | 0.507|
| I                                | 265 (50.5)             | 125 (55.6)               |     |
| II                               | 53 (10.1)              | 17 (7.6)                 |     |
| III                              | 157 (29.9)             | 65 (28.9)                |     |
| IV                               | 50 (9.5)               | 18 (8.0)                 |     |
| **Infection pathway**            |                        |                          | 0.915|
| NMHR                             | 304 (57.9)             | 134 (59.6)               |     |
| MSM                              | 158 (30.1)             | 65 (28.9)                |     |
| Others                           | 63 (12.0)              | 26 (11.6)                |     |
| **Occupation**                   |                        |                          | 0.506|
| Farmer                           | 128 (24.4)             | 62 (27.6)                |     |
| Business people                  | 99 (18.9)              | 45 (20.0)                |     |
| House keeping                    | 124 (23.6)             | 40 (17.8)                |     |
| Worker                           | 73 (13.9)              | 32 (14.2)                |     |
| Others                           | 101 (19.2)             | 46 (20.4)                |     |
| **History STD**                  |                        |                          | 0.490|
| Yes                              | 88 (16.8)              | 30 (13.3)                |     |
| No                               | 310 (59.0)             | 137 (60.9)               |     |
| Missing                          | 127 (24.2)             | 58 (25.8)                |     |
| **Participants category**        |                        |                          | 0.730|
| Fixed population                 | 407 (77.5)             | 177 (78.7)               |     |
| Floating population              | 118 (22.5)             | 48 (21.3)                |     |
| **Education**                    |                        |                          | 0.097|
| Illiterate or elementary school  | 192 (36.6)             | 85 (37.8)                |     |
| Senior middle school             | 78 (14.9)              | 38 (16.9)                |     |
| Junior high school               | 207 (39.4)             | 71 (31.6)                |     |
| College and above                | 48 (9.1)               | 31 (13.8)                |     |
| **Marital status**               |                        |                          | 0.523|
| Married                          | 277 (52.8)             | 113 (50.2)               |     |
| Unmarried                        | 248 (47.2)             | 112 (49.8)               |     |
| **Disease stage**                |                        |                          | 0.379|
| HIV                              | 278 (53.0)             | 127 (56.4)               |     |
| AIDS                             | 247 (47.0)             | 98 (43.6)                |     |
| **Origin of identification**     |                        |                          | 0.418|
| CDC                              | 136 (25.9)             | 49 (21.8)                |     |
| Hospital                         | 317 (60.4)             | 140 (62.2)               |     |
| Others                           | 72 (13.7)              | 36 (16.0)                |     |
| **Viral load, copies/mL**        |                        |                          | 0.508|
| <200                             | 413 (78.7)             | 175 (77.8)               |     |
| 200–1000                         | 16 (3.0)               | 4 (1.8)                  |     |
| ≥1000                            | 96 (18.3)              | 46 (20.4)                |     |
| **Continuous variables**         |                        |                          |     |
| Age, year                        | 49.7 (37.3,63.5)       | 48.2 (38.2,61.9)         | 0.624|
| Body mass index, kg/m²           | 21.3 (19.3,23.7)       | 21.2 (19.1,23.3)         | 0.347|
| CD4+ T-lymphocyte count, cells/μL | 208.3 (166.0,283.0)   | 203.0 (193.9,299.0)      | 0.430|
| CD8+ T-lymphocyte count, cells/μL | 861.0 (535.0,1272.0)  | 838.0 (581.1,1208.0)     | 0.870|
| White blood cell, 10⁹/L          | 5.3 (4.2,6.8)          | 5.1 (4.1,6.5)            | 0.175|
| Platelet, 10⁹/L                  | 186.0 (144.0,224.0)    | 191.5 (145.0,236.0)      | 0.495|
| Haemoglobin, g/L                 | 136.7 (118.0,149.0)    | 135.0 (119.0,150.0)      | 0.933|
| Creatinine, μmol/L               | 70.0 (58.6,81.0)       | 70.1 (58.3,83.0)         | 0.610|
| Triglyceride, mmol/L             | 1.5 (1.0,2.4)          | 1.4 (1.0,2.4)            | 0.576|
| Total cholesterol, mmol/L        | 4.1 ± 0.9              | 4.1 ± 0.9                | 0.717|
| Fasting plasma glucose, mmol/L   | 5.3 ± 4.7               | 5.4 ± 4.6                | 0.916|
| Aspartate transaminase, U/L      | 25.0 (19.0,34.0)       | 23.0 (19.0,35.0)         | 0.449|
| Alanine aminotransferase, U/L    | 21.6 (15.0,34.0)       | 21.0 (15.0,35.0)         | 0.761|
| Total bilirubin, μmol/L          | 10.8 (7.7,15.4)        | 10.3 (7.2,15.6)          | 0.678|

Abbreviations: NMHR, Non-marital heterosexual transmission; MSM, men who have sex with men; CDC, centre for disease prevention and control; STD, sexually transmitted disease.
set and 72.4 per 1000 person-years in the validation set. The average overall survival for the training and validation sets were 2.73 and 2.76 years, respectively.

3.2. Nomogram screening depending on the training set

On the univariate survival analysis, a total of 13 factors including CD4, VL and HB were detected to be statistically associated with the mortality of PLHIV depending on the univariate survival analysis (Table 2). While in the multivariable Cox proportion hazard regression models in which variables with p-value less than 0.2 were included based on the results of the univariate analysis, we found that only CD4, VL, HB, GLU and CR were directly and independently linked to the HIV/AIDS-related survival time (Table 2). To formulate an optimal nomogram model, the individual and combined performances of these five factors were then comprehensively evaluated using ROC analysis. As could be seen in Fig. 1, the individual AUCs of GLU, CR, CD4, VL and HB were 0.59, 0.51, 0.84, 0.85 and 0.75, respectively. Moreover, ROC curves with the combination1 (CD4, VL, HB, CR, and GLU) and combination2 (CD4, VL, and HB) performed similarly (AUC = 0.94 vs 0.93, χ² = 3.165, p-value = 0.075). To simplify the model by including only those most statistically significant variables, GLU and CR were removed from the model because of their relatively small AUC. So, a nomogram for predicting the mortality of PLHIV was preliminarily constructed with three factors containing CD4, VL, and HB (Figs. 1, 2, and Supplement Table S2). The associated concordance index (c-index) was 0.91 (95% CI, 0.86–0.97), which indicated that about 91% of the probability of individual mortality would be correctly predicted by the nomogram model. Furthermore, as could be seen in Fig. 2, each selected biomarker was assigned a corresponding score according to its value on the nomogram. After calculating the total score, we drew a vertical line using the total score and obtained the individual probability of PLHIV survival. The as-

| Table 2 | Univariate and multivariable Cox hazards analysis of the training cohort. |
|---------|---------------------------------------------------------------|
| Variables | Univariate HR(95% CI) | p-value | Multivariate AHR(95% CI) | p-value |
| WHO | | | | |
| I | 1.442(0.680,3.059) | 0.340 | 1.376(0.569,3.330) | 0.478 |
| II | 2.698(1.675,4.348) | <0.001 | 1.596(0.944,2.698) | 0.081 |
| III | 5.113(2.977,8.782) | <0.001 | 1.870(0.997,3.507) | 0.051 |
| IV | 0.109(0.055,0.216) | <0.001 | 0.832(0.331,2.094) | 0.697 |
| Disease stage (HIV) | | | | |
| Origin of identification | | | | |
| Hospital | 0.407(0.234,0.706) | 0.001 | 0.648(0.354,1.185) | 0.159 |
| CDC | 0.461(0.231,0.919) | 0.028 | 0.577(0.256,1.305) | 0.187 |
| Others | 0.999(0.998,0.999) | <0.001 | 0.995(0.992,0.999) | 0.007 |
| Viral load, copies/mL | 4.882(3.881,5.142) | <0.001 | 4.025(3.029,5.348) | <0.001 |
| Platelet, 10⁹/L | 1.003(1.001,1.005) | 0.006 | 1.001(0.998,1.004) | 0.412 |
| Haemoglobin, g/L | 0.970(0.963,0.978) | <0.001 | 0.988(0.979,0.998) | 0.014 |
| Aspartate transaminase, U/L | 1.005(1.002,1.009) | 0.004 | 0.993(0.984,1.003) | 0.159 |
| Body mass index, kg/m² | 0.893(0.817,0.952) | 0.001 | 1.019(0.950,1.094) | 0.593 |
| Total cholesterol, mmol/L | 0.547(0.440,0.681) | <0.001 | 1.006(0.794,1.273) | 0.964 |
| Total bilirubin, μmol/L | 1.010(1.001,1.019) | 0.031 | 1.018(0.998,1.038) | 0.077 |
| Fasting plasma glucose, mmol/L | 1.021(1.003,1.040) | 0.023 | 1.064(1.027,1.101) | <0.001 |
| Statistically non-significant factors | | | | |
| Marital status | 1.369(0.932,2.011) | 0.110 | 0.764(0.483,1.209) | 0.250 |
| Occupation | 0.952(0.500,1.781) | 0.859 | 0.646(0.329,1.273) | 0.228 |
| NMHR | 0.530(0.323,0.869) | 0.012 | 1.046(0.581,1.883) | 0.881 |
| Others | 0.728(0.395,1.341) | 0.309 | 0.688(0.317,1.403) | 0.303 |
| Education | 0.941(0.828,1.070) | 0.356 | 0.941(0.828,1.070) | 0.356 |
| Farmer | 0.308(0.142,0.669) | 0.003 | 0.385(0.157,0.941) | 0.036 |
| History STD | 0.818(0.449,1.494) | 0.514 | 0.941(0.828,1.070) | 0.356 |
| Others | 0.728(0.395,1.341) | 0.309 | 0.688(0.317,1.403) | 0.303 |
| Illiterate or elementary school | 0.952(0.500,1.781) | 0.859 | 0.646(0.329,1.273) | 0.228 |
| Senior middle school | 0.631(0.329,1.273) | 0.290 | 0.385(0.157,0.941) | 0.036 |
| Junior high school | 0.915(0.517,1.619) | 0.760 | 0.941(0.828,1.070) | 0.356 |
| College and above | 1.011(0.656,1.557) | 0.962 | 0.941(0.828,1.070) | 0.356 |
| Marital status | 1.369(0.932,2.011) | 0.110 | 0.764(0.483,1.209) | 0.250 |
| White blood cell, 10⁹/L | 0.992(0.924,1.065) | 0.831 | 0.764(0.483,1.209) | 0.250 |
| Creatinine, μmol/L | 1.009(0.998,1.019) | 0.102 | 1.013(1.002,1.024) | 0.023 |
| Alanine aminotransferase, U/L | 1.003(0.998,1.007) | 0.235 | 1.013(1.002,1.024) | 0.023 |
| Triglyceride, mmol/L | 1.024(0.890,1.179) | 0.738 | 1.004(0.794,1.273) | 0.964 |

Abbreviations: NMHR, Non-marital heterosexual transmission; MSM, men who have sex with men; CDC, center for disease prevention and control; STD, sexually transmitted disease.
Fig. 1. The ROC curve of the prognostic nomogram, CD4, VL, HB, CR, GLU and combined group in the training and validation set.
Notes: The ROC curve for training cohort (a) and validation set (b).
Abbreviations: VL, viral load; HB, haemoglobin; GLU, fasting plasma glucose; Combine, CD4, VL, HB, CR and GLU; CR, creatinine; ROC, receiver operating characteristic.

Fig. 2. Nomogram of laboratory index for predicting HIV/AIDS-related survival in the initiated of ART.
Note: The scores of each variable were added to obtain the total score, and a vertical line was drawn on the total score to obtain the corresponding probability of death.
Abbreviations: HB, haemoglobin.

3.3. Validation of the nomogram based on the validation set
To verify the efficacy of the nomogram to predict survival of PLHIV, we conducted comprehensive validations of the nomogram based on the validation set as follows: First, we determined the c-index with 0.92 (95% CI, 0.82–1.00). Second, as could be seen in Fig. 1, its associated AUC in the ROC analysis achieved as high as 0.95 (95% CI, 0.91–1.00). Third, calibration curves also displayed high consistency in the prediction of PLHIV’s survival time, especially in the first year after receiving ART (Fig. 3).

3.4. Comparison between nomogram and laboratory test indicators
To further validate and compare the superiority of the laboratory indicators and the nomogram in assessing the survival of PLHIV, we plotted the ROC curves of CD4, HB, GLU, VL, CR, a full combined model containing these five indicators together and the nomogram (Fig. 1) in the training set and validation set, respec-
Fig. 3. Calibration curves for predicting overall survival rate by the nomogram in the training and validation set.

Notes: Calibration curves of the prognostic nomogram for 1-year overall survival (a), 2-year overall survival (b) and 3-year overall survival (c) in the training set; calibration curves for 1-year overall survival (d), 2-year overall survival (e), and 3-year overall survival (f) in the validation set.

3.5. DCA curve analysis

As was shown in Fig. 4, whether in the training set or validation set, the nomogram and the full combined model all performed outstandingly in various predictors regardless of the threshold, which ensured to achieve maximum clinical benefit. Overall, the DCA curve indicated that a nomogram was feasible to make valuable and profitable judgments. Furthermore, among the three detected factors included in the nomogram, we also observed that VL was more beneficial than the other two routine clinical laboratory indicators in the prediction of PLHIV survival.
could be found in Fig. 6. The HR (95% CI) for the moderate and par- 
sic groups was 20.50 (4.73–88.81) and 11.12 (5.53–22.36) as com- 
pared to people with the low- or moderate risk. The Kaplan-
Meier curves in both the training and validation sets all clearly 
disclosed that the nomogram was stable to forecast the probability 
of survival in PLHIV after receiving ART.

4. Discussion

Although PLHIV may live longer than before with the 
widespread usage of ART, accurate prediction of the survival for 
PLHIV remains to be necessary and a major challenge for health-
care providers since it can effectively improve PLHIV’s survival. Be-
sides, a prediction helps develop appropriate healthcare for PLHIV 
and guidelines for HIV/AIDS administration [27]. For clinicians or 
disease control staff, it is also highly beneficial in the personal-
ized administration of PLHIV and optimizing the delivery of lim-
ited health resources [28]. Based on this nested case-control study 
from a HIV/AIDS cohort in the Wenzhou area, we comprehensively 
assessed the relationship between some routine laboratory test 
markers and the mortality of PLHIV. An optimal prognostic nomo-
gram model, containing VL, CD4 and HB, and with satisfying sta-
bility and accuracy, for the prediction of PLHIV mortality was suc-
cessfully developed and carefully evaluated.

Available pieces of evidence suggest that a nomogram can be 
effective in predicting the prognosis of patients and it’s simple and 
intuitive features are easy for clinical staff to interpret [29,30]. To 
the best of our knowledge, the present study is the first report on 
developing a nomogram to predict the survival probability for PL-
HIV using some baseline laboratory testing indicators. In the multi-

variable Cox proportion hazard regression model, we observed that 
CD4, HB and VL were all independently associated with the mor-
tality of PLHIV. When the three variables mentioned above were 
incorporated into a nomogram model, we achieved a bootstrapped 
corrected concordance index as 0.914 in the training set. A satisfy-
ing agreement with good calibration (c-index = 0.917) and high 
accuracy (AUC = 0.95) was also observed in the independent vali-
dation set.

In the present study, the nomogram did not include clinical 
signs and symptoms such as the WHO clinical stage, which had 
been reported to be associated with the mortality of PLHIV. The 
possible reason was that the laboratory indicators were more sen-
sitive in predicting mortality than those clinical signs and symp-
toms. A previous study has shown that establishing a haemato-
logical index to assess the status of disease progression in PL-
HIV may be more useful to clinicians than available methods [31].

In recent years, many studies have reported that some labora-
tory tests are closely related to the death of PLHIV. Engsig et al. 
[32] found that virally suppressed HIV-positive individuals on ART 
who do not achieve a CD4 count >200 cells/μL have substantially 
increased long-term mortality. Shoko et al. [33] also suggested that 
VL was a better predictor to forecast PLHIV mortality than CD4.

A strong association of CD4 at the start of therapy with subse-
quent survival in PLHIV was also detected [34]. Meanwhile, HB 
was also independently associated with the survival and progres-
sion of PLHIV [7]. Fortunately, our results disclosed that VL, CD4 
HB were also significantly linked to the survival of PLHIV and 
well consistent with these published findings. Elevated VL and de-
creased CD4 levels were markers of immune dysregulation and on-
going inflammatory processes, which might induce increased mor-
tality of PLHIV. As can be seen in Supplement Fig. S2, the higher 
level of VL the lower survival probability of PLHIV ($\chi^2 = 380.358$, $P < 0.001$). Meanwhile, we also find that elevated CD4 level is sig-
nificantly associated with reduced death risk of PLHIV (Supplement 
Fig. S3a), which is consistent with previous reports [35]. Fur-

thermore, haemoglobin level was also observed to be independently 
associated with the mortality of PLHIV (Supplement Fig. S3b). Pos-
sible explanations are as follows: (1) Chronic inflammation con-
tributes to the development of anaemia is observed not only in 
the general population but also in PLHIV. Previous reports suggest 
that anaemia is associated with the mortality of PLHIV because of 
the haematological abnormality [36–41]. (2) PLHIV with long-term 
anæmia is commonly due to an unhealthy lifestyle, more likely to 
have poor treatment compliance, which will largely increase the 
death risk to some extent. Although ART is an effective measure to 
reduce the prevalence of anaemia, a large number of PLHIV are still 
in the trouble of unresolved anaemia persistently or developing 
to anaemia [42], this is consistent with our findings. Furthermore,
our findings also revealed that VL was the most important predictor with an excellent predictive ability (AUC = 0.8536). It also proved that HIV RNA would be an optimal predictor of long-term mortality than other laboratory markers [33]. However, as a single predictor is highly susceptible to offset, its prediction accuracy would be ineffective, which would greatly limit its results extrapolation [21]. To overcome or avoid the limitation of a single predictor and achieve higher predictive accuracy, we combined three detected predictors to construct a nomogram model in the present study. Our data confirmed that the nomogram was much better in the prediction of PLHIV survival than that of any single predictor in both the training set (AUC = 0.93) and the validation set (AUC = 0.95). Besides, the DCA curve has been commonly used to evaluate the efficacy of specific clinical approaches in many studies [43,44]. In the present study, we also used the DCA curve to check out the potential clinical effects of the nomogram and our findings showed that the nomogram was more useful than any other indicator in predicting HIV/AIDS related mortality.

Several strengths could be found in the present study. First, our data suggested that the nomogram was a good option to effectively forecast the death risk of PLHIV. Second, to obtain better performance in the actual prediction, we also calculated a total score of the death risk by the nomogram. PLHIV could be classified into different categories according to the cut-off points determined by X-tile analysis. This would be very favourable to promote the precise prevention and personalized health management of PLHIV to maximize cost-effectiveness. Furthermore, our findings came from a PSM-based nested case-control study, in which the cases and controls originated from the same population-based cohort. This study design would be advantageous to reduce the selection bias, improve statistical efficiency, and make our conclusion more robust and reliable.

Limitations also existed in this study. First, the nomogram model was established mainly based on the baseline level of VL, CD4 and HB. As the levels of these three laboratory markers could not maintain stable throughout the whole follow-up period, it would partly affect the accuracy of the prediction, and perhaps the reason of the differences between the predicted and observed mortalities, especially in the 2- or 3-year survivals after receiving ART (Fig. 3). Fortunately, the differences between the predicted 1-year mortality and the observed one in both the training and validation sets were very similar, which indicated that the baseline laboratory marker-based nomogram was more suitable for the prediction of short-term death risk in PLHIV after receiving ART. Second, several ARTs had been provided to the identified PLHIV during the study period. This would also affect the performance of the nomogram to some extent. As we know, China carried out free ART strategies to HIV/AIDS throughout their lives. However, as the largest developing country with a large number of PLHIV, China could not afford too many kinds of ART strategies, and the commonly used antiviral drugs were limited, which would reduce the impacts due to ART strategies on our findings to some extent. Third, the participants were only from Wenzhou, which might limit the extrapolation of our findings to the whole PLHIV.
In conclusion, our findings suggest that the nomogram constructed by routine laboratory markers can serve accurate and favourable prognostic prediction in the mortality of PLHIV. This may be very beneficial in promoting the precise prevention and personalized administration of PLHIV.

Declarations of Competing Interest

All authors declare no potential conflicts of interest.

CRediT authorship contribution statement

Xiangqing Hou: Conceptualization, Formal analysis, Writing - original draft, Data curation. Dayong Wang: Conceptualization, Writing - original draft, Data curation. Jingjue Zuo: Data curation. Jushuang Li: Data curation. Tao Wang: Data curation. Chengnan Guo: Data curation. Fang Peng: Writing - review & editing, Data curation. Dehua Su: Data curation. Lina Zhao: Data curation. Zhenmiao Ye: Data curation. Hemei Zhang: Data curation. Chao Zheng: Data curation. Guangyun Mao: Conceptualization, Formal analysis, Writing - original draft, Data curation.

Acknowledgements

We would like to thank the AIDS Prevention and Control Information System (AIDS-PCS) developer and investigators. We appreciate the contributions of team members from Wenzhou centre for disease control and prevention (CDC) and Wenzhou medical university. We also thank all PLHIV who participated in this nested case-control study.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ebiom.2019.09.031.

References

[1] Mallewa J, Szubert AJ, Mugyenyi P. Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial. Lancet HIV 2018;5(8):e340–9.
[2] Ford N, Ball A, Baggaley R, et al. The WHO public health approach to HIV treatment and care: looking back and looking ahead. Lancet Infect Dis 2010;10(9):521–30.
[3] Collins J, Journaud G, Hansudewachralin K, et al. Long-term survival of HIV-infected children receiving antiretroviral therapy in Thailand: a 5-year observational cohort study. Clin Infect Dis 2010;51(12):1449–57.
[4] Gupta-Wright A, Corbett EL, Wilson D, et al. Risk score for predicting mortality including urine lipoarabinomannan detection in hospital inpatients with HIV-associated tuberculosis in sub-Saharan Africa: derivation and external validation cohort study. PLoS Med 2019;16(4):e1002776.
[5] Cameron S, Quiros C, Saubi N, et al. Full blood count values as a predictor of 30-day postoperative mortality in HIV/AIDS patients in the era of highly active antiretroviral therapy. Ann Surg 2012;256(1):170–6.
[6] Furlan J, Jimenez-Gordo AM, Madero R, et al. Development and validation of a prognostic nomogram for terminally ill cancer patients. J Natl Cancer Inst 2011;103(21):1613–20.
[7] Wang X, Mao M, He Z, et al. Development and validation of a prognostic nomogram in AFP-negative hepatocellular carcinoma. Int J Biol Sci 2019;15(1):221–8.
[8] Justice AC, Modur SP, Janet P, Tate S. Predictive accuracy of the veterans aging cohort study index for mortality with HIV infection: a North American cross-cohort analysis. J Acquir Immune Defic Syndr 2013;62(2):149–63.
[9] Mocroft A, Ledergerber B, Zilmer K. Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. AIDS 2007;21:1867–75.
[10] Robbins GK, Johnson KL, Chang Y, et al. Predicting virologic failure in an HIV clinic. Clin Infect Dis 2010;50(5):779–86.
[11] Wang L, Balavarca Y, van der Geest L, et al. Development and validation of a prognostic model to predict the probability of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study. BMC Med 2019;17(1):66.
[12] Han M, Chen Q, Yao T, et al. Design and implementation of a China comprehensive AIDS response programme (China CARES), 2003-08. Int J Epidemiol 2010;39(Suppl 2):i47–55.
[13] Zhang FJ, Pan J, Yu L. Current progress of China’s free art program. Cell Res. 2015;25(11–12):877–87.
[14] Trickey A, May MT, Schommer P, et al. CD4+CD8 ratio and CD8 count as prognostic markers for mortality in human immunodeficiency virus-infected patients on antiretroviral therapy: the Antiretroviral Therapy Cohort Collaboration (ART-CC). Clin Infect Dis 2017;65(5):599–663.
[15] Zou L, Liang S, Sun X, et al. Drug resistance and virological failure among HIV-infected patients after a decade of antiretroviral treatment expansion in eight provinces of China. PLoS One 2016;11(12):e0166661.
[16] McNerney B, Vandermerwoude A. National age-of-consent laws and adolescent HIV testing in sub-Saharan Africa: a propensity-score matched study. Bull World Health Organ 2019;97(1):42–50.
[17] Van Der Berg HA, Occam’s razor: from Ockham’s via moderna to modern data science. Sci Prog 2018;101(3):261–72.
[18] Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15(4):361–87.
[19] Huyse P, Sauverbout W. A new measure of prognostic separation in survival data. Stat Med 2004;23(5):723–48.
[20] Ingle SM, May MT, Gill MJ, et al. Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. Clin Infect Dis 2014;59(2):287–97.
[21] KK B, HG, T, B. Adherence and viral suppression among participants of the patient-centered HIV care model project—a collaboration between communi- ty-based pharmacists and HIV clinical providers. Clin Infect Dis 2019.
[22] Chen L, Cai BR, Zhou CJ, et al. A sample model established by S-index predicting overall survival after curative resection of primary hepatocellular carcinoma. Cancer Manag Res 2019;11:693–703.
[23] Lei Z, Li J, Yu D, et al. Nomogram for preoperative estimation of microvascular invasion risk in hepatocellular carcinoma within the Milan criteria. JAMA Surg 2016;151(4):356–63.
[24] Aziz N, Quint J, Breen EC, et al. 30-Year Longitudinal study of hematologi- cal parameters of HIV-1 negative men participating in Los Angeles Multicenter AIDS Cohort Study (MACS, Lab Med 2012) 50(1):64–72.
[25] Engsig FN, Zangerle R, Katarusic O, et al. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis 2014;53(9):1321–2.
[26] Shohou C, Chokhovu D. A superiority of viral load over CD4 cell count when predicting mortality in HIV patients on therapy. BMC Infect Dis 2019;19(1):169.
[27] May MT, Vehreschild J, Trickey A, et al. Mortality according to CD4 count at start of combination antiretroviral therapy among HIV-infected patients fol- lowed for up to 15 years after start of treatment: collaborative cohort study. Clin Infect Dis 2016;62(12):1571–7.
[28] Hulgan T, Shepherd BE, Raffanti SP, et al. Absolute count and percentage of poor outcome of pneumonia among HIV-infected patients initiating highly active antiretroviral therapy. J Infect Dis 2007;195(4):25–31.
[29] Shivakoti R, Yang WT, Gupte N, et al. Concurrent anemia and elevated C-reactive protein predicts HIV clinical treatment failure, including tuberculosis, after antiretroviral therapy initiation. Clin Infect Dis 2015;61(1):102–10.
[30] Stämpfli SF, Schmid UD, Wolf P, et al. CD4+ lymphocytes as independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J Infect Dis 2007;195(4):25–31.
[31] Shivakoti R, Yang WT, Gupte N, et al. Concurrent anemia and elevated C-reactive protein predicts HIV clinical treatment failure, including tuberculosis, after antiretroviral therapy initiation. Clin Infect Dis 2015;61(1):102–10.
[32] McDermid JM, Hennig BJ, van de Sande M, et al. Host iron redistribution as a risk factor for incident tuberculosis in HIV infection: an 11-year retrospective cohort study. BMC Infect Dis 2013;13:48.
[33] Harris RJ, Sterne JA, Abgrall S, et al. Prognostic importance of anaemia in HIV-1 infected patients starting antiretroviral therapy: collaborative analy- sis of prospective cohort studies in industrialized countries. Antivir Ther 2012;17(8):959–67.
[34] Belperio PS, Rhew DC. Prevalence and outcomes of anaemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med 2004;116(Suppl 7A):275–435.
[40] McDermid JM, Jaye A, Schim MF, et al. Elevated iron status strongly predicts mortality in West African adults with HIV infection. J Acquir Immune Defic Syndr 2007;46(4):498–507.

[41] Rawat R, Humphrey JH, Ntozini R, et al. Elevated iron stores are associated with HIV disease severity and mortality among postpartum women in Zimbabwe. Public Health Nutr 2009;12(9):1321–9.

[42] Quiros-Roldan E, Castelli F, Lanza P, et al. The impact of antiretroviral therapy on iron homeostasis and inflammation markers in HIV-infected patients with mild anemia. J Transl Med 2017;15(1):256.

[43] Lamain-de Ruiter M, Kwee A, Naaktgeboren CA, et al. External validation of prognostic models to predict risk of gestational diabetes mellitus in one Dutch cohort: prospective multicentre cohort study. BMJ 2016;354:i4338.

[44] Kerr KF, Brown MD, Zhu K, et al. Assessing the clinical impact of risk prediction models with decision curves: guidance for correct interpretation and appropriate use. J Clin Oncol 2016;34(21):2534–40.